Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA12 | O43570 | 9/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 11/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22339175 | 0.85 | TDP1 (0.46) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL4595826 | 0.81 | CA12 (0.40) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL1979026 | 0.80 | TDP1 (0.55) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL13055395 | 0.80 | TDP1 (0.55) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL12482641 | 0.78 | TDP1 (0.56) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL23643797 | 0.78 | MEN1 (0.50) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL24224621 | 0.77 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL20812668 | 0.77 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL5311882 | 0.77 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL28210550 | 0.77 | TDP1 (0.70) | TDP1MEN1GAAKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | TDP1 607/4885MEN1 2029/4885GAA 1363/4885 |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | TDP1 607/4885MEN1 2029/4885GAA 1363/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | TDP1 607/4885MEN1 2029/4885GAA 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.